Thelansis

Recurrent or Refractory Ascites Market Outlook Thelansis’s “Recurrent or Refractory Ascites Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Recurrent or Refractory Ascites treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impac...

  Ascites refer to the abnormal accumulation of fluid within the peritoneal cavity, primarily associated with cirrhosis and often indicating the transition from compensated to decompensated cirrhosis. Refractory ascites (RA) is a term defined by the International Club of Ascites (ICA) as ascites that recur within 4 weeks after large-volume paracentesis (LVP) and are resistant to medical therapy. Recurrent ascites, defined as ascites recurring at least three times within 12 months, impact survival differently than RA, and its effects on survival are yet unknown. Refractory ascites, occurring in 5%–10% of all patients with cirrhotic ascites, is associated with a high mortality rate, with an average 1-year survival rate of around 50%. Large-volume paracentesis, the primary treatment for refractory ascites, involves directly aspirating more than 5 liters of ascites. While LVP can rapidly control massive ascites and reduce hospital stays compared to diuretics, it does not affect the m...